Bristol-Myers Squibb Co. will buy Celgene Corp. for about $74 billion, creating one of the largest pharmaceutical companies and combining two significant cancer medicine businesses.

GlaxoSmithKline agreed to buy U.S. cancer specialist Tesaro for $5.1 billion, a costly investment to rebuild the pharma business by new Chief Executive Emma Walmsley that unnerved investors.

Denmark-based Genmab released top-line data from the Phase III MAIA clinical trial of Darzalex (daratumumab), a drug licensed to Johnson & Johnson’s Janssen.

A single leukemia cell inadvertently got mixed in with a batch of a patient’s immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported.

Shares of Molecular Templates were up more than 52 percent after announcing a deal with Takeda that could be worth up to $632 million to develop CD38-targeted engineered toxin bodies.

Amgen unveiled data at a multiple myeloma conference for AMG-420, which targets B-cell maturation antigen (BCMA).

J&J topped analysts’ estimates for Q2 2018 profit and revenue with strong demand for the cancer drugs Zytiga and Darzalex.

Amgen Inc. and The University of Texas MD Anderson Cancer Center announced two multi-year collaborative research deals for a broad range of cancer therapeutics. The cancers studied will include leukemia, myelodysplastic syndromes (MDS), multiple myeloma, small-cell lung cancer, and other non-lung cancers with small-cell histologies.

Genmab and J&J’s Janssen division pulled the plug on the Phase Ib/II trial of daratumumab in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced or metastatic NSCLC.

Johnson & Johnson reported a strong first-quarter 2018 with $20 billion in sales that was fueled by significant growth in the company’s pharmaceuticals business.